Citation Impact
1 by Nobel laureates 66 standout
Citing Papers
Glioblastoma Therapy: Past, Present and Future
2024 Standout
Targeted protein degradation: from mechanisms to clinic
2024 Standout
Works of Diane E. Durecki being referenced
Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.
2022
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
2012
Author Peers
| Author | Molecular Biology | Oncology | Genetics | Hematology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Diane E. Durecki | 314 | 166 | 40 | 316 | 8 | 366 | |
| Francis J. Welsh | 3 | 6 | 18 | 9 | 510 | ||
| L. A. Morrissey | 84 | 15 | 28 | 902 | |||
| S. Aurtenetxea | 5 | 286 | |||||
| Yuanyuan Tan | 1 | 28 | 345 | ||||
| Ho-In Lee | 5 | 15 | 810 |
All Works
Login with ORCID to disown or claim papers
Loading papers...